Moorfields study investigates treatment effectiveness for wet AMD
The publicly-available data set used in the research is the largest single-centre cohort of patients receiving wet AMD treatment in the world
Scientists have emphasised the value of open access, anonymised data sets following a study investigating the effectiveness of ranibizumab and aflibercept in the treatment of wet age-related macular degeneration (AMD).
The research, which was published in BMJ Open, highlighted that both treatments result in an improvement in vision.
Younger patients had a greater improvement in vision than older patients and those who received more injections also showed more improvement.
The study used depersonalised medical records from 3357 wet AMD patients showing the number of injections each patient received and how their vision changed over two years of treatment.
The publicly-available data set is the largest single-centre cohort of patients receiving treatment for wet AMD in the world.
Corresponding author, Pearse Keane, from Moorfields Eye Hospital, highlighted that electronic medical records have the potential to make retrospective study populations more representative of real life.
“This study shows the value of making this data anonymised and publicly available, to provide a valuable open science resource,” he said.
Image credit: Pixabay